Sign up to save your podcasts
Or
Share Why Numinus Made This $6M Strategic Move?
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Why Numinus Made This $6M Strategic Move?
On today's episode of TDR's Trade To Black podcast, we're joined by Payton Nyquvest, Founder and CEO of Numinus Wellness (OTCMKTS: NUMIF), to discuss the latest advancements in psychedelic-assisted therapy. Nyquvest talks about Numinus' recent $6 million funding success, strategic partnerships, and the future of MDMA-assisted therapy for mental health.
Key highlights include:
🎙️The significance of the FDA's acceptance of MDMA for therapy and its implications for Numinus and the field at large.
💡The strategic collaboration with Optimi Health Corp, aiming to enhance the development and delivery of psychedelic therapies.
🤝The financial strategies Numinus is employing to reduce its burn rate to zero, ensuring sustainability and growth.
🌐The importance of experiential training for therapists in psychedelic-assisted therapies and how Numinus is leading the charge.
💼The potential impact of Health Canada's stance on psychedelic therapies following FDA approvals.
🎤Nyquvest's vision for the future of psychedelic-assisted therapy and Numinus' role in making these transformative treatments accessible to those in need.
This episode provides a comprehensive look into the efforts and challenges of integrating psychedelic-assisted therapies into mainstream healthcare, showcasing Numinus Wellness Inc.'s pivotal role in this emerging field.
View all episodes
By Dales Media Group
5
77 ratings
On today's episode of TDR's Trade To Black podcast, we're joined by Payton Nyquvest, Founder and CEO of Numinus Wellness (OTCMKTS: NUMIF), to discuss the latest advancements in psychedelic-assisted therapy. Nyquvest talks about Numinus' recent $6 million funding success, strategic partnerships, and the future of MDMA-assisted therapy for mental health.
Key highlights include:
🎙️The significance of the FDA's acceptance of MDMA for therapy and its implications for Numinus and the field at large.
💡The strategic collaboration with Optimi Health Corp, aiming to enhance the development and delivery of psychedelic therapies.
🤝The financial strategies Numinus is employing to reduce its burn rate to zero, ensuring sustainability and growth.
🌐The importance of experiential training for therapists in psychedelic-assisted therapies and how Numinus is leading the charge.
💼The potential impact of Health Canada's stance on psychedelic therapies following FDA approvals.
🎤Nyquvest's vision for the future of psychedelic-assisted therapy and Numinus' role in making these transformative treatments accessible to those in need.
This episode provides a comprehensive look into the efforts and challenges of integrating psychedelic-assisted therapies into mainstream healthcare, showcasing Numinus Wellness Inc.'s pivotal role in this emerging field.
More shows like The Dales Report | Trade to Black
View all
Blunt Business
40 Listeners
Modern Wisdom
3,752 Listeners
Mining Stock Daily
95 Listeners
The Pomp Podcast
1,833 Listeners
The Cannabis Investing Podcast
204 Listeners
Cannabis Investing Network
70 Listeners
The Prof G Pod with Scott Galloway
5,415 Listeners
The Memo by Howard Marks
401 Listeners
The Dime
104 Listeners
Huberman Lab
28,547 Listeners
Honestly with Bari Weiss
8,601 Listeners
On The Tape with Danny Moses
155 Listeners
High Spirits: The Cannabis Business Podcast
6 Listeners
Higher Exchanges
11 Listeners
Prof G Markets
1,164 Listeners